SangStat To Introduce SangCya At 20%-28% Discount To Novartis Neoral

SangStat SangCya will be introduced at a 20%-28% discount to Novartis' cyclosporine product Neoral. The company estimated that the difference in pricing will lead to an annual savings of approximately $1,200 per patient receiving the anti-rejection therapy following organ transplantation.